The main objective of the study was to describe the prevalence of GLP-1 receptor agonist use and to provide baseline, pre-uptake, population-level estimates of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) and mortality among obese US adults without diabetes using pooled NHANES data from 2011 to 2018. Here, GLP1R is linked to stroke disorder.